Safety and efficacy of first-line bevacizumab with FOLFOX, XELOX, FOLFIRI and fluoropyrimidines in metastatic colorectal cancer: the BEAT studyEric Van Cutsem, David Cunningham, Fernando Rivera et al.|Annals of Oncology|2009Cited by 534
Preliminary safety of bevacizumab with first-line Folfox, Capox, Folfiri and capecitabine for mCRC—First B.E.A.TrialScott Berry, Eric VanCutsem, David Cunningham et al.|Journal of Clinical Oncology|2006Cited by 44
Final efficacy results for bevacizumab plus standard first-line chemotherapies in patients with metastatic colorectal cancer: First BEATScott Berry, David Cunningham, Eric Van Cutsem et al.|Journal of Clinical Oncology|2008Cited by 22
Preliminary efficacy of bevacizumab with first-line FOLFOX, XELOX, FOLFIRI and monotherapy for mCRC: First BEATrialAlbrecht Kretzschmar, David Cunningham, Eric Van Cutsem et al.|Journal of Clinical Oncology|2007Cited by 19
3020 POSTER Preliminary efficacy of Bevacizumab with first-line Folfox, Xelox, Folfiri and fluoropyrimidines for mCRC: First BEAT trialScott Berry, Eric Van Cutsem, David Cunningham et al.|European Journal of Cancer Supplements|2007Cited by 9